These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31952623)

  • 21. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies.
    Rutrick D; Learned SM; Boyett B; Hassman D; Shinde S; Zhao Y
    J Subst Use Addict Treat; 2023 Nov; 154():209155. PubMed ID: 37657559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methamphetamine/amphetamine use over time among persons with opioid use disorders treated with buprenorphine/naloxone versus extended-release naltrexone.
    Tsui JI; Campbell ANC; Pavlicova M; Choo TH; Lee JD; Cook RR; Shulman M; Nunes EV; Rotrosen J
    Drug Alcohol Depend; 2022 Jul; 236():109469. PubMed ID: 35605529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
    Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
    J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buprenorphine Naloxone and Extended Release Injectable Naltrexone for the Treatment of Opioid Use Disorder Among a Veteran Patient Sample: A Retrospective Chart Review.
    Shirk SD; Ameral V; Kraus SW; Houchins J; Kelly M; Pugh K; Reilly E; Desai N
    J Dual Diagn; 2021; 17(3):207-215. PubMed ID: 34176448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended-release Buprenorphine Administered at Discharge in Hospitalized Persons With Opioid Use Disorder: A Case Series.
    Hansen ER; South AM; Lofwall MR; Fanucchi LC
    J Addict Med; 2024 Jan-Feb 01; 18(1):65-67. PubMed ID: 37874645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pregnant and Postpartum Individuals' Knowledge, Attitudes, and Perceptions of Extended-release Buprenorphine for Treatment of Opioid Use Disorder.
    Lai M; Bowman J; Charles J; Smid MC
    J Addict Med; 2023 May-Jun 01; 17(3):342-345. PubMed ID: 37267186
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence.
    Farrell M; Shahbazi J; Byrne M; Grebely J; Lintzeris N; Chambers M; Larance B; Ali R; Nielsen S; Dunlop A; Dore GJ; McDonough M; Montebello M; Nicholas T; Weiss R; Rodgers C; Cook J; Degenhardt L;
    Int J Drug Policy; 2022 Feb; 100():103492. PubMed ID: 34736130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Baseline- and treatment-associated pain in the X:BOT comparative effectiveness study of extended-release naltrexone versus buprenorphine-naloxone for OUD.
    Wang AL; Shulman M; Choo TH; Pavlicova M; Langleben DD; Nunes EV; Rotrosen J
    Addict Biol; 2022 Mar; 27(2):e13112. PubMed ID: 34877769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Case Report: Rapid Micro-Induction of Buprenorphine/Naloxone to Administer Buprenorphine Extended-Release in an Adolescent With Severe Opioid Use Disorder.
    Azar P; Wong JSH; Jassemi S; Moore E; Vo DX; Nikoo M; Young S
    Am J Addict; 2020 Nov; 29(6):531-535. PubMed ID: 32346944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.
    D'Onofrio G; Hawk KF; Herring AA; Perrone J; Cowan E; McCormack RP; Dziura J; Taylor RA; Coupet E; Edelman EJ; Pantalon MV; Owens PH; Martel SH; O'Connor PG; Van Veldhuisen P; DeVogel N; Huntley K; Murphy SM; Lofwall MR; Walsh SL; Fiellin DA
    Contemp Clin Trials; 2021 May; 104():106359. PubMed ID: 33737199
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.
    Petrakis I; Springer SA; Davis C; Ralevski E; Gu L; Lew R; Hermos J; Nuite M; Gordon AJ; Kosten TR; Nunes EV; Rosenheck R; Saxon AJ; Swift R; Goldberg A; Ringer R; Ferguson R
    Addict Sci Clin Pract; 2022 Jan; 17(1):6. PubMed ID: 35101115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experience and response to a randomised controlled trial of extended-release injectable buprenorphine versus sublingual tablet buprenorphine and oral liquid methadone for opioid use disorder: protocol for a mixed-methods evaluation.
    Lowry N; Cowden F; Day E; Gilvarry E; Johnstone S; Murray R; Kelleher M; Mitcheson L; Marsden J
    BMJ Open; 2022 Oct; 12(10):e067194. PubMed ID: 36270754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Explaining differential effects of medication for opioid use disorder using a novel approach incorporating mediating variables.
    Rudolph KE; Díaz I; Hejazi NS; van der Laan MJ; Luo SX; Shulman M; Campbell A; Rotrosen J; Nunes EV
    Addiction; 2021 Aug; 116(8):2094-2103. PubMed ID: 33340181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of long-acting injectable buprenorphine in the correctional setting.
    Martin RA; Berk J; Rich JD; Kang A; Fritsche J; Clarke JG
    J Subst Abuse Treat; 2022 Nov; 142():108851. PubMed ID: 35939914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Choice of extended release medication for OUD in young adults (buprenorphine or naltrexone): A pilot enhancement of the Youth Opioid Recovery Support (YORS) intervention.
    Wenzel K; Selby V; Wildberger J; Lavorato L; Thomas J; Fishman M
    J Subst Abuse Treat; 2021 Jun; 125():108306. PubMed ID: 34016297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder.
    Kranzler HR; Lynch KG; Crist RC; Hartwell E; Le Moigne A; Laffont CM; Andorn AC
    Int J Neuropsychopharmacol; 2021 Feb; 24(2):89-96. PubMed ID: 32920647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.
    Lintzeris N; Dunlop AJ; Haber PS; Lubman DI; Graham R; Hutchinson S; Arunogiri S; Hayes V; Hjelmström P; Svedberg A; Peterson S; Tiberg F
    JAMA Netw Open; 2021 May; 4(5):e219041. PubMed ID: 33970256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone.
    Greiner MG; Shulman M; Scodes J; Choo TH; Pavlicova M; Opara O; Campbell ANC; Novo P; Fishman M; Lee JD; Rotrosen J; Nunes EV
    Subst Use Misuse; 2022; 57(11):1732-1742. PubMed ID: 35975917
    [No Abstract]   [Full Text] [Related]  

  • 39. Treating Opioid Use Disorder With a Monthly Subcutaneous Buprenorphine Depot Injection: 12-Month Safety, Tolerability, and Efficacy Analysis.
    Andorn AC; Haight BR; Shinde S; Fudala PJ; Zhao Y; Heidbreder C; Learned SM; Fox NL; Nadipelli VR; Hassman D; Rutrick D
    J Clin Psychopharmacol; 2020; 40(3):231-239. PubMed ID: 32282418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A qualitative study comparing physician-reported barriers to treating addiction using buprenorphine and extended-release naltrexone in U.S. office-based practices.
    Andraka-Christou B; Capone MJ
    Int J Drug Policy; 2018 Apr; 54():9-17. PubMed ID: 29324253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.